# INmune Bio (INMB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INMB
## Company Profile
- Ticker: INMB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 2.04 USD
- Market cap: 37751066.36 USD
- Last updated: 2026-08-12
## Business Overview
### Innate-Immune Therapeutics
INmune Bio develops therapies that modify innate immune responses. Its programs span cell therapy, neuroinflammation and cancer biology.
### CORDStrom
CORDStrom is an allogeneic umbilical-cord-derived stromal-cell therapy being developed for recessive dystrophic epidermolysis bullosa, a severe inherited skin disorder.
### XPro in Alzheimer's Disease
XPro1595 is a selective soluble-TNF inhibitor in clinical development for early Alzheimer's disease. The program is designed to suppress harmful neuroinflammation while preserving beneficial transmembrane-TNF signaling.
### INB03 Oncology Program
INB03 applies the same soluble-TNF mechanism to cancer, with preclinical work evaluating whether it can overcome treatment resistance and reduce metastasis in HER2-positive disease.
### INKmune
INKmune is a cell-based medicine designed to prime a patient's natural-killer cells into tumor-killing memory-like cells. It is being evaluated in an open-label Phase 1/2 prostate-cancer study.
## Why The Stock Is Moving

As of Aug 12, 2026, INMB closed down 1.92% at $2.04. No new same-company headline was identified in the current news window.

## Future Catalysts

- UK marketing-authorization submission for CORDStrom around mid-summer 2026.
- European Medicines Agency filing for CORDStrom following the UK submission.
- FDA BLA submission for CORDStrom in the fourth quarter of 2026.

## Recent News
- 2026-08-06 20:00 EST — [INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress](https://biopharmsignal.com/news/INMB/inmune-bio-inc-announces-second-quarter-2026-results-and-highlights-regulatory-m-fcee152b) — Source: INmune Bio
- 2026-07-31 11:00 EST — [INmune Bio Receives R&D Rebates of Approximately $4.6 Million](https://biopharmsignal.com/news/INMB/inmune-bio-receives-r-d-rebates-of-approximately-4-6-million-b9fb7430) — Source: INmune Bio
- 2026-07-31 11:00 EST — [INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th](https://biopharmsignal.com/news/INMB/inmune-bio-inc-to-report-second-quarter-2026-financial-results-and-provide-corpo-908a49f8) — Source: INmune Bio
- 2026-07-30 11:00 EST — [INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform](https://biopharmsignal.com/news/INMB/inmune-bio-establishes-scientific-advisory-board-to-support-late-stage-developme-c0e6866f) — Source: INmune Bio
- 2026-07-20 11:00 EST — [INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform](https://biopharmsignal.com/news/INMB/inmune-bio-completes-commercial-manufacturing-milestone-supporting-planned-globa-65214648) — Source: INmune Bio